Cosyntropin
Active ingredient: Cosyntropin
In short: Cosyntropin for injection is indicated, in combination with other diagnostic tests, for use as a diagnostic agent in the screening of adrenocortical insufficiency in adults and pediatric patients.
What is Cosyntropin used for?
Cosyntropin for injection is indicated, in combination with other diagnostic tests, for use as a diagnostic agent in the screening of adrenocortical insufficiency in adults and pediatric patients.
Cosyntropin dosage
•In general, stop glucocorticoids and spironolactone on the day of cosyntropin for injection testing. However, long-acting glucocorticoids may need to be stopped for a longer period before cosyntropin for injection testing .
•Stop estrogen-containing drugs four to six weeks before cosyntropin for injection testing .
•The recommended dose of cosyntropin for injection in adults is 0.25 mg to be administered by intravenous or intramuscular injection.
•The recommended dose of cosyntropin for injection in pediatric patients, aged birth to 17 years, to be administered by intravenous or intramuscular injection is presented in Table 1.
Table 1. Recommended Cosyntropin for Injection Dose for Pediatric Patients
Age | Recommended Dose | Volume of Reconstituted Solution
Birth to less than 2 years | 0.125 mg | 0.5 mL
2 to 17 years | 0.25 mg | 1 mL
•Aseptically reconstitute the lyophilized powder in the vial using 1 mL of 0.9% Sodium Chloride Injection, USP and gently swirl.
•After reconstitution, the final concentration of cosyntropin for injection reconstituted solution is 0.25 mg/mL.
•Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The reconstituted cosyntropin for injection solution should be clear and colorless, and free of particulates. If cosyntropin for injection solution is cloudy or contains particulates, do not administer.
•If the cosyntropin for injection reconstituted solution is not used immediately, discard the unused cosyntropin for injection reconstituted solution.
•Cosyntropin for injection may be administered by intramuscular or intravenous injection.
•Obtain blood sample for baseline serum cortisol. Obtain blood samples again for assessment of cortisol levels exactly 30 minutes and 60 minutes after administration of cosyntropin for injection.
•Stimulated plasma cortisol levels of less than 18 mcg/dL at 30- or 60-minutes post cosyntropin for injection are suggestive of adrenocortical insufficiency. Cutoff values for exclusion of adrenocortical insufficiency may vary according to the assay used. Test results can be affected by concomitant medications and certain medical conditions .
How to take Cosyntropin — instructions & advice from the label
Advise the patient and/or caregiver to read the FDA-approved patient labeling (Patient Information).
Hypersensitivity Reactions, Including Anaphylaxis
Inform patients and/or caregivers of the early signs of hypersensitivity reactions including rash, hives, itching, facialswelling, tightness of the chest, and wheezing .
Drug Interference with Cosyntropin for Injection Testing
Advise patients and/or caregivers to stop taking glucocorticoids and spironolactone on the day of cosyntropin for injection testing. However, for patients taking long-acting glucocorticoids, advise them to stop for longer periods before cosyntropin for injection testing. Advise patients to stop taking estrogen-containing drugs four to six weeks before cosyntropin for injection testing [see
Dosage and Administration (2.1), Warnings and Precautions (5.2), and Drug Interactions (7)].
Manufactured by Oakwood Labs, for
Sandoz Inc., Princeton, NJ 08540
Warnings & precautions
Do not take this medicine if: Cosyntropin for injection is contraindicated in patients with a history of hypersensitivity to cosyntropin or to any excipients of cosyntropin for injection. Reactions have included anaphylaxis .
Cosyntropin for injection hypersensitivity reactions including anaphylaxis have been reported. Monitor patients for hypersensitivity reactions and treat as needed.
Cortisol levels and subsequent diagnosis of adrenocortical insufficiency following cosyntropin for injection administration may be inaccurate if patients are on certain medications because of their effect on cortisol or cortisol binding globulin levels.
Glucocorticoids and spironolactone may result in falsely elevated cortisol levels. Stop these drugs on the day of cosyntropin for injection testing. Long-acting glucocorticoids may need to be stopped for a longer period before cosyntropin for injection testing .
Estrogen-containing drugs increase cortisol binding globulin levels which can increase plasma total cortisol levels. To obtain accurate plasma total cortisol levels, stop estrogen containing drugs four to six weeks before cosyntropin for injection testing to allow cortisol binding globulin levels to return to levels within the reference range . Alternatively, concomitant measurement of cortisol binding globulin at the time of testing can be done; if cortisol binding globulin levels are elevated, plasma total cortisol levels are considered inaccurate.
Any condition that elevates or lowers cortisol binding globulin levels may increase or decrease plasma total cortisol levels, respectively. Cortisol binding globulin levels can be low in cirrhosis or nephrotic syndrome. Measure cortisol binding globulin levels as necessary to ensure accuracy of interpretation of plasma total cortisol levels.
Cosyntropin side effects
Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been identified during post approval use of cosyntropin for injection:
•anaphylactic reaction
•bradycardia
•tachycardia
•hypertension
•peripheral edema
•rash
Drug interactions
•Accuracy of the test results can be affected by concomitant medications. Plasma cortisol levels and subsequent diagnosis of adrenocortical insufficiency following cosyntropin for injection administration may be inaccurate if patients are on certain medications because of their effect on cortisol or cortisol binding globulin levels .
•Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels. Stop these drugs on the day of cosyntropin for injection testing. Long-acting glucocorticoids may need to be stopped for a longer period before cosyntropin for injection testing.
•Estrogen: May elevate plasma total cortisol levels. Stop estrogen containing drugs 4 to 6 weeks before cosyntropin for injection testing to allow cortisol binding globulin levels to return to levels within the reference range. Alternatively, concomitant measurement of cortisol binding globulin at the time of testing can be done; if cortisol binding globulin levels are elevated, plasma total cortisol levels are considered inaccurate.
About this medicine
Cosyntropin is an adrenocorticotropic hormone (ACTH). Cosyntropin is synthetic beta 1 - 24 corticotropin, a synthetic subunit of ACTH. It is an open chain polypeptide containing, the first 24 of the 39 amino acids of natural ACTH in sequence from N terminal. The sequence of amino acids in the 1 - 24 compound is as follows:
Molecular Formula: C136H210N40O31S
Molecular Weight: 2933 g/mol.
Cosyntropin for injection is a sterile lyophilized powder in single-dose vials containing 0.25 mg of cosyntropin and 10 mg of mannitol.
How it works: Cosyntropin exhibits the full corticosteroidogenic activity of natural ACTH. Various studies have shown that the biologic activity of ACTH resides in the N-terminal portion of the molecule and that the 1-20 amino acid residue is the minimal sequence retaining full activity. Partial or complete loss of activity is noted with progressive shortening of the chain beyond 20 amino acid residues.
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 1342169c-e214-4f22-8363-1fd45b85d1e8. Read the full official label on DailyMed.